Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE
Volume 27, Issue 3, Pages 346-349Publisher
SPRINGER VERLAG
DOI: 10.1007/s002590050044
Keywords
[I-123]FP-CIT; dopamine transporter imaging; animal studies; dopaminergic medication; Parkinson's disease; single-photon emission tomography
Ask authors/readers for more resources
The recently developed radioligand [I-123]FP-CIT is suitable for clinical single-photon emission tomography (SPET) imaging of the dopamine (DA) transporter in vivo. To date it has remained unclear whether dopaminergic medication influences the striatal [I-123]FP-CIT binding. The purpose of this study was to investigate the influence of this medication on [I-123]FP-CIT binding in the brain. We used an animal model in which we administered dopaminomimetics, antipsychotics and an antidepressant. In vivo [I-123]FP-CIT binding to the DA and serotonin transporters was evaluated after subchronic and acute administration of the drugs. The administered medication induced small changes in striatal [I-123]FP-CIT binding which were not statistically significant. As expected, the DA reuptake blocker GBR 12,909 induced a significant decrease in [I-123]FP-CIT binding. [I-123]FP-CIT binding in the serotonin-rich hypothalamus was decreased only after acute administration of fluvoxamine, The results of this study suggest that dopaminergic medication will not affect the results of DA transporter SPET imaging with [I-123]FP-CIT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available